ArticleCentral European journal of urology2025
Clinical characteristics and outcomes of men <60 years undergoing HoLEP: A retrospective single-center study.
Article in Central European journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Erectile and ejaculatory outcomes after HoLEP: A longitudinal analysis during the learning curve.Central European journal of urology · 2026Article
- Holmium laser enucleation of the prostate in the oldest-old: a comparative analysis across the extremes of age.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Data on holmium laser enucleation of the prostate (HoLEP) in men ≤60 are limited. This study aimed to characterize the clinical presentation and outcomes of this population. Material and methods: This retrospective study comprised 750 consecutive HoLEPs between 1/2020 and 11/2024. Patients were categorized by age: ≤60, 61-70, 71-80, and >80 years. The data retrieved from the medical records included age, International Prostate Symptom Scores (IPSS), uroflowmetry, preoperative prostate volume (via abdominal ultrasound), comorbidities, previous prostate surgery, presence of a preoperative indwelling urinary catheter or chronic retention, bladder stones, operative time, complications, hospital stay, and outcome. Results: Presentation with absolute indication (indwelling catheter and/or chronic retention) was more prevalent in the ≤60 and >80 age groups (p <0.001). The youngest group had smaller prostate volume (78 vs 90 ml, p = 0.004), fewer comorbidities, shorter surgery (70 vs 90 minutes, p <0.001), lower "beach balls" rate (2% vs 15%, p = 0.008), and shorter hospitalization (1 vs 1.5 days, p <0.001). Younger patients had lower postoperative IPSS (4 vs 7 points, p = 0.036), while the quality of life scores were similar. The overall rate of incidental prostate cancer increased with age, but not significantly. The youngest group presented with only International Society of Urological Pathology (ISUP) 1, while older groups had a higher rate of ISUP grade ≥2 (0 vs 18-25%, p <0.05). Complications were similar across age groups. Conclusions: HoLEP is an effective treatment for men of all ages. Men under 60 or over 80 were more frequently treated for absolute indications, while those aged 61-80 were more often treated for relative indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.